References
- S. Gandolfi, J. P. Laubach, T. Hideshima, D. Chauhan, K. C. Anderson and P. G. Richardson, The proteasome and proteasome inhibitors in multiple myeloma, Cancer Metastasis Rev. 36(4) (2017) 561–584; https://doi.org/10.1007/s10555-017-9707-8
- M. Diaz-delCastillo, A. D. Chantry, M. A. Lawson and A. M. Heegaard, Multiple myeloma – A painful disease of the bone marrow, Semin. Cell Dev. Biol. 112 (2021) 49–58; https://doi.org/10.1016/j.semcdb.2020.10.006
- E. S. Ring, M. A. Lawson, J. A. Snowden, I. Jolley and A. D. Chantry, New agents in the treatment of myeloma bone disease, Calcif. Tissue Int. 102(2) (2018) 196–209; https://doi.org/10.1007/s00223-017-0351-7
- F. Marofi, S. Tahmasebi, H. S. Rahman, D. Kaigorodov, A. Markov, A. V. Yumashev, N. Shomali, M. S. Chartrand, Y. Pathak, R. N. Mohammed, M. Jarahian, R. Motavalli and F. Motavalli Khiavi, Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism, Stem Cell Res. Ther. 12(1) (2021) Article ID 217 (21 pages); https://doi.org/10.1186/s13287-021-02283-z
- B. Noel, S. K. Singh, J. W. Lillard, Jr. and R. Singh, Role of natural compounds in preventing and treating breast cancer, Front Biosci. 12(1) (2020) 137–160; https://doi.org/10.2741/S544
- M. Ezzati, B. Yousefi, K. Velaei and A. Safa, A review on anti-cancer properties of quercetin in breast cancer, Life Sci. 248 (2020) Article ID 117463; https://doi.org/10.1016/j.lfs.2020.117463
- Y. Wang, W. Ma and W. Zheng, Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention, Mol. Clin. Oncol. 1(2) (2013) 215–219; https://doi.org/10.3892/mco.2012.36
- Y. Baba and Y. Kato, Deguelin, a novel anti-tumorigenic agent in human esophageal squamous cell carcinoma, EBioMedicine 26 (2017) 10; https://doi.org/10.1016/j.ebiom.2017.11.010
- X. D. Xu, Y. Zhao, M. Zhang, R. Z. He, X. H. Shi, X. J. Guo, C. J. Shi, F. Peng, M. Wang, M. Shen, X. Wang, X. Li and R. Y. Qin, Inhibition of autophagy by deguelin sensitizes pancreatic cancer cells to doxorubicin, Int. J. Mol. Sci. 18(2) (2017) Article ID 370 (13 pages); https://doi.org/10.3390/ijms18020370
- X. H. Peng, P. Karna, R. M. O’Regan, X. Liu, R. Naithani, R. M. Moriarty, W. C. Wood, H. Y. Lee and L. Yang, Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells, Mol. Pharmacol. 71(1) (2007) 101–111; https://doi.org/10.1124/mol.106.027367
- G. Murillo, X. Peng, K. E. Torres and R. G. Mehta, Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway, Cancer Prev. Res. 2(11) (2009) 942–950; https://doi.org/10.1158/1940-6207.CAPR-08-0232
- T. Yi, H. Li, X. Wang and Z. Wu, Enhancement radiosensitization of breast cancer cells by deguelin, Cancer Biother. Radiopharm. 23(3) (2008) 355–362; https://doi.org/10.1089/cbr.2007.0452
- E. B. Kurutas, The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state, Nutr. J. 15(1) (2016) Article ID 71 (22 pages); https://doi.org/10.1186/s12937-016-0186-5
- K. A. Kang, M. J. Piao, Y. S. Ryu, Y. J. Hyun, J. E. Park, K. Shilnikova, A. X. Zhen, H. K. Kang, Y. S. Koh, Y. J. Jeong and J. W. Hyun, Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells, Int. J. Oncol. 51(4) (2017) 1169–1178; https://doi.org/10.3892/ijo.2017.4091
- S. Deng, M. K. Shanmugam, A. P. Kumar, C. T. Yap, G. Sethi and A. Bishayee, Targeting autophagy using natural compounds for cancer prevention and therapy, Cancer 125(8) (2019) 1228–1246; https://doi.org/10.1002/cncr.31978
- A. Lichota and K. Gwozdzinski, Anticancer activity of natural compounds from plant and marine environment, Int. J. Mol. Sci. 19(11) (2018); Article ID 3533 (38 pages); https://doi.org/10.3390/ijms19113533
- A. J. Robles, S. Cai, R. H. Cichewicz and S. L. Mooberry, Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer, Breast Cancer Res. Treat. 157(3) (2016) 475–488; https://doi.org/10.1007/s10549-016-3841-9
- L. Chen, K. Jiang, H. Chen, Y. Tang, X. Zhou, Y. Tan, Y. Yuan, Q. Xiao and K. Ding, Deguelin induces apoptosis in colorectal cancer cells by activating the p38 MAPK pathway, Cancer Manag. Res. 11 (2019) 95–105; https://doi.org/10.2147/CMAR.S169476
- W. Kang, X. Zheng, P. Wang and S. Guo, Deguelin exerts anticancer activity of human gastric cancer MGC-803 and MKN-45 cells in vitro, Int. J. Mol. Med. 41(6) (2018) 3157–3166; https://doi.org/10.3892/ijmm.2018.3532
- K. Liu, M. Zheng, R. Lu, J. Du, Q. Zhao, Z. Li, Y. Li and S. Zhang, The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review, Cancer Cell Int. 20 (2020) Article ID 213 (16 pages); https://doi.org/10.1186/s12935-020-01304-w
- S. Dalton, Cell cycle regulation of the human cdc2 gene, Embo J. 11(5) (1992) 1797–1804; https://doi.org/10.1002/j.1460-2075.1992.tb05231.x
- X. Yu, Q. Liang, W. Liu, L. Zhou, W. Li and H. Liu, Deguelin, an aurora B Kinase inhibitor, exhibits potent anti-tumor effect in human esophageal squamous cell carcinoma, EBioMedicine 26 (2017) 100–111; https://doi.org/10.1016/j.ebiom.2017.10.030
- W. Li, X. Yu, X. Ma, L. Xie, Z. Xia, L. Liu, J. Wang, H. Zhou, X. Zhou, Y. Yang and H. Liu, Deguelin attenuates non-small cell lung cancer cell metastasis through inhibiting the CtsZ/FAK signaling pathway, Cell Signal. 50 (2018) 131–141; https://doi.org/10.1016/j.cellsig.2018.07.001
- S. R. Boreddy and S. K. Srivastava, Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model, Oncogene 32(34) (2013) 3980–3991; https://doi.org/10.1038/onc.2012.413
- J. Yang, J. Nie, X. Ma, Y. Wei, Y. Peng and X. Wei, Targeting PI3K in cancer: mechanisms and advances in clinical trials, Mol. Cancer 18(1) (2019) Article ID 26 (28 pages); https://doi.org/10.1186/s12943-019-0954-x
- B. D. Manning and L. C. Cantley, AKT/PKB signaling: navigating downstream, Cell 129(7) (2007) 1261–1274; https://doi.org/10.1016/j.cell.2007.06.009
- G. M. Nitulescu, M. Van De Venter, G. Nitulescu, A. Ungurianu, P. Juzenas, Q. Peng, O. T. Olaru, D. Gradinaru, A. Tsatsakis, D. Tsoukalas, D. A. Spandidos and D. Margina, The Akt pathway in oncology therapy and beyond (Review), Int. J. Oncol. 53(6) (2018) 2319–2331; https://doi.org/10.3892/ijo.2018.4597